Inari Medical reported strong revenue growth of 21% in Q3 2024, reaching $153 million. However, the company experienced a GAAP operating loss of $13.6 million, compared to an operating income of $2.1 million in the same quarter last year. The company raises full year 2024 revenue guidance to $601.5 million to $604.5 million.
Revenue reached $153 million in Q3 2024, a 21% increase year-over-year.
GAAP operating loss was $13.6 million in Q3 2024, compared to a $2.1 million operating income in the same quarter of last year.
Non-GAAP operating loss was $0.4 million in Q3 2024, compared to a $4.8 million non-GAAP operating income in the same quarter of last year.
Cash, cash equivalents, and short-term investments totaled $112 million as of Q3 2024.
Inari raises full year 2024 revenue guidance to $601.5 million to $604.5 million and expects to reach sustained operating profitability in the first half of 2025.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance